成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 136-95-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 136-95-8
Chemical Structure| 136-95-8
Structure of 136-95-8 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 136-95-8 ]

Related Doc. of [ 136-95-8 ]

Alternatived Products of [ 136-95-8 ]
Product Citations

Product Citations      Expand+

Ryan M. Hacker ; Daniela M. Grimard ; Katie A. Morgan , et al. DOI: PubMed ID:

Abstract: With the recent clinical success of anti-amyloid-β (Aβ) monoclonal antibodies, there is a renewed interest in agents which target the Aβ peptide of Alzheimer's disease (AD). Metal complexes are particularly well-suited for this development, given their structural versatility and ability to form stabile interactions with soluble Aβ. In this report, a small series of ruthenium–arene complexes were evaluated for their respective ability to modulate both the aggregation and cytotoxicity of Aβ. First, the stability of the complexes was evaluated in a variety of aqueous media where the complexes demonstrated exceptional stability. Next, the ability to coordinate and modulate the Aβ peptide was evaluated using several spectroscopic methods, including thioflavin T (ThT) fluorescence, dynamic light scattering (DLS), and transmission electron microscopy (TEM). Overall, the complex RuBO consistently gave the greatest inhibitory action towards Aβ aggregation, which correlated with its ability to coordinate to Aβ in solution. Furthermore, RuBO also had the lowest affinity for serum albumin, which is a key consideration for a neurotherapeutic, as this protein does not cross the blood brain barrier. Lastly, RuBO also displayed promising neuroprotective properties, as it had the greatest inhibition of Aβ-inducted cytotoxicity.

Purchased from AmBeed: ; ;

Walczak, Juliusz Maksymilian ; Iwaszkiewicz-Grzes, Dorota ; Ziomkowska, Michalina , et al. DOI: PubMed ID:

Abstract: The group of 18 new amide derivatives of mycophenolic acid (MPA) and selected heterocyclic amines was synthesised as potential immunosuppressive agents functioning as inosine-5′-monophosphate dehydrogenase (IMPDH) uncompetitive inhibitors. The synthesis of 14 of them employed uronium-type activating system (TBTU/HOBt/DIPEA) while 4 of them concerned phosphonic acid anhydride method (T3P/Py) facilitating amides to be obtained in moderate to excellent yields without the need of phenolic group protection. Most of optimised protocols did not require complicated reaction work-ups, including chromatographic, solvent-consuming methods. The biological activity assay was performed on the T-Jurkat cell line and peripheral mononuclear blood cells (PBMCs) which are both dedicated for antiproliferative activity determination. Each of designed derivatives was characterised by reduced cytotoxicity and benzoxazole analogue (A2) revealed the most promising activity. Subsequently, an observed structure-activity relationship was discussed.

Keywords: Mycophenolic acid ; amide derivatives ; heterocycles ; benzoxazole ; IMPDH inhibition

Purchased from AmBeed: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Product Details of [ 136-95-8 ]

CAS No. :136-95-8 MDL No. :MFCD00005785
Formula : C7H6N2S Boiling Point : -
Linear Structure Formula :(C7H4NS)NH2 InChI Key :UHGULLIUJBCTEF-UHFFFAOYSA-N
M.W : 150.20 Pubchem ID :8706
Synonyms :

Calculated chemistry of [ 136-95-8 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 44.02
TPSA : 67.15 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.09 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.56
Log Po/w (XLOGP3) : 1.59
Log Po/w (WLOGP) : 1.89
Log Po/w (MLOGP) : 1.25
Log Po/w (SILICOS-IT) : 2.47
Consensus Log Po/w : 1.75

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.44
Solubility : 0.547 mg/ml ; 0.00364 mol/l
Class : Soluble
Log S (Ali) : -2.61
Solubility : 0.368 mg/ml ; 0.00245 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.59
Solubility : 0.384 mg/ml ; 0.00256 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.92

Safety of [ 136-95-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P305+P351+P338 UN#:N/A
Hazard Statements:H302-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 136-95-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 136-95-8 ]

[ 136-95-8 ] Synthesis Path-Downstream   1~14

  • 1
  • [ 136-95-8 ]
  • [ 1001-26-9 ]
  • [ 58099-45-9 ]
  • 2
  • [ 136-95-8 ]
  • [ 1186-73-8 ]
  • [ 224313-89-7 ]
  • 3
  • [ 136-95-8 ]
  • [ 1186-73-8 ]
  • N3-(benzo<d><1,3>thiazolyl)-2-hydroxy-4-oxo-4H-benzo<4,5>thiazolo<3,2-a>pyrimidinecarboxamide [ No CAS ]
  • 4
  • [ 136-95-8 ]
  • [ 627-18-9 ]
  • [ 58929-72-9 ]
  • 2-imino-3-(γ-hydroxypropyl)benzothiazoline [ No CAS ]
  • bis[3-(γ-hydroxypropyl)benzothiazol-2-ylidene]ammonium bromide [ No CAS ]
  • 5
  • [ 136-95-8 ]
  • [ 1798-83-0 ]
  • 2,4-bis-(4-chlorobenzoyl)-2,3-dihydro-1H-pyrido[2,1-b][1,3]benzothiazole [ No CAS ]
  • 6
  • [ 136-95-8 ]
  • [ 17823-69-7 ]
  • [ 183998-94-9 ]
  • 7
  • [ 136-95-8 ]
  • [ 2012-74-0 ]
  • [ 1009206-06-7 ]
  • 8
  • [ 136-95-8 ]
  • [ 39539-66-7 ]
  • [ 1280873-18-8 ]
YieldReaction ConditionsOperation in experiment
General procedure: we started with the4-methyl-1-piperazine carbonyl chloride (Scheme 1). By reactionof this compound with the corresponding amine in dry pyridineas solvent, at room temperature, the urea derivative crystallizedas hydrochloride. The hydrochloride was dissolved in water, basifiedwith aqueous Na2CO3 (10%) and extracted with CH2Cl2. The organiclayer was dried over Na2SO4 and the solvent was removed toafford a residue, which was purified by chromatography column toobtain the corresponding ureas 1-5.
  • 10
  • [ 136-95-8 ]
  • [ 105763-77-7 ]
  • N2,N4-di(benzo[d]thiazol-2-yl)-6-methoxyquinazoline-2,4-diamine [ No CAS ]
  • 11
  • [ 136-95-8 ]
  • (1,3-bis(2,6-diisopropylphenyl)imidazolidin-2-yl)(difluoromethylthio)silver [ No CAS ]
  • [ 943-08-8 ]
  • 12
  • [ 136-95-8 ]
  • [ 931-53-3 ]
  • [ 33985-71-6 ]
  • N-cyclohexyl-2-(2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-9-yl)benzo[d]imidazo[2,1-b]thiazol-3-amine [ No CAS ]
YieldReaction ConditionsOperation in experiment
72% In toluene; at 100℃; for 0.166667h;Microwave irradiation; Sealed tube; General procedure: General Procedure (GP): In a MW sealed-tube equipped with a magnetic stirring bar, to a 0.5 M solution of aldehyde (1.0 equiv.) in anhydrous toluene [0.5 M], amine (1.0 equiv.) and isocyanide (1.0 equiv.) were added sequentially and the reaction mixture was MW-heated (100 oC,150 W) for 10 minutes. Then, the solvent was removed until dryness and the crude was immediately purified by silica-gel column chromatography using a mixture of hexanes with ethyl acetate (7/3; v/v) to afford the corresponding products 1a-w.
  • 13
  • [ 136-95-8 ]
  • [ 41360-32-1 ]
  • C15H12N2O4S2 [ No CAS ]
  • 14
  • [ 136-95-8 ]
  • [ 4481-28-1 ]
  • C15H11N3O2S [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records
; ;